Amorphical has appointed Eden Ben as chief executive officer, as the company accelerates its regulatory strategy in the US and Europe and advances a pipeline of nano-amorphous mineral-based therapeutics.

Ben, who has a background in biomedical engineering and management, will lead efforts to translate Amorphical’s discoveries into pharmaceutical assets. The company’s proprietary nano-amorphous mineral technology regulates cellular pH and offers superior bioavailability compared with conventional mineral forms. These advantages underpin programmes in oncology, metabolic and endocrine disorders, and musculoskeletal health.

Ben said: “Our nano-amorphous mineral technology, more than a million times smaller than conventional mineral forms, represents a new frontier in medicine. It allows us to move beyond symptom management toward true disease-modifying therapies. We are committed to delivering a safe and effective nano-mineral platform that we hope will address many indications for patients worldwide.”

The company is entering clinical development after more than a decade of early access and compassionate use programmes. These initiatives provided insights into safety, tolerability, and patient-reported outcomes that are now shaping Amorphical’s clinical and regulatory approach. Current studies include a phase 2 trial for hypoparathyroidism under FDA oversight, with further studies planned in pancreatic cancer, osteoporotic fractures, and Crohn’s disease.

Amorphical’s pharmaceutical-grade, GMP-compliant facility supports the development and scaling of its therapeutics. This infrastructure will play a critical role in bringing validated nano-amorphous mineral-based treatments to market.

Ran Gorelik, member of the board of directors, said the appointment reflects Amorphical’s ambitions: “Eden’s deep expertise is perfectly aligned with our operational priority to deliver safe, effective, and breakthrough nano-amorphous mineral treatments for serious diseases. His appointment marks a critical step as we accelerate development, regulatory, and clinical milestones to unlock the great potential of our clinical approach.”

With Ben at the helm, Amorphical is positioning itself to expand access to its innovative platform and meet significant unmet needs across oncology, endocrine disorders, and musculoskeletal conditions.